Indiscreet Prescribing Of Antibiotics Cause Of Microbial Resistance Minister In RS

New Delhi: Indiscreet prescribing of antibiotics is one of the major causes of microbial resistance in the country, Minister of State for Health S P Singh Baghel told Rajya Sabha on Tuesday.

The National Centre for Disease Control (NCDC) conducted a point prevalence survey (PPS) on antibiotic use at 20 tertiary care government hospitals (NAC-NET sites).

This study was conducted amongst 9,653 eligible patients admitted to these 20 hospitals, Baghel said in a written reply.

The survey found that 71.9 per cent of the patients received antibiotics.

Of those who were prescribed antibiotics, 54.8 per cent received antibiotics for prophylactic indications (surgical prophylaxis 37.3 per cent and medical prophylaxis 17.5 per cent).

“Indiscreet prescribing of antibiotics is one of the major causes of microbial resistance in the country,” he said.

The Union health ministry has initiated several initiatives to promote judicious use of antimicrobials.

The ministry launched the Red Line awareness campaign on antimicrobial resistance, urging people not to use medicines marked with a red vertical line, including antibiotics, without a doctor’s prescription.

The Indian Council of Medical Research (ICMR) has released treatment guidelines for antimicrobial use in common syndromes in which guidelines for the use of antibiotics for viral bronchitis and low-grade fever antibiotics are included in Schedule H and H1 of the Drugs Rules, 1945.

These drugs have specific caution labelling requirements and are sold only under the prescription of a registered medical practitioner.

The supply of a drug specified in Schedule H1 is recorded in a separate register and such records, which are maintained for three years, are open for inspection.

The Central Drugs Standard Control Organisation (CDSCO) has placed 24 hi-end antimicrobials under schedule H1 by issuing notification, Baghel stated.

Related Posts

Gene Therapy for Cholesterol: Initial Test Results Cheer

Eli Lilly working on single-dose drug to be administered via IV for long-term gain Mumbai: For millions of heart patients struggling with elevated levels of cholesterol, there is a ray…

US Biotech Regeneron to launch Global Capability Centre in Hyderabad

Regeneron Pharmaceuticals, Inc. has announced plans to establish the Regeneron Global Capability Centre (GCC) in Hyderabad, a strategic investment that deepens its global operations and scales business functions to advance…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Gene Therapy for Cholesterol: Initial Test Results Cheer

Gene Therapy for Cholesterol: Initial Test Results Cheer

US Biotech Regeneron to launch Global Capability Centre in Hyderabad

US Biotech Regeneron to launch Global Capability Centre in Hyderabad

Popped the Pill, Paid the Price to Potentially Fatal Skin Syndrome

Popped the Pill, Paid the Price to Potentially Fatal Skin Syndrome

Former Advisor to India’s Union Health Ministry gets Quite a Feather in his Cap

Former Advisor to India’s Union Health Ministry gets Quite a Feather in his Cap

Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

STF busts fake meds racket spread across 6 states

STF busts fake meds racket spread across 6 states